肿瘤精准医学:肿瘤药师的新实践模式与角色
本文描述了威斯康星大学、印第安纳大学和Moffitt癌症中心由肿瘤药师开发并主导的三种精准医学实践模式(门诊、临床会诊服务和分子肿瘤委员会),总结其共同点与实施策略,并建议加强药师在基因组肿瘤学方面的教育和培训。
要点
- 肿瘤药师可主导门诊、会诊服务和分子肿瘤委员会三种精准医学实践模式。
- 三种模式的共同点包括药师领导、具体治疗建议、超说明书用药获取和研究环节。
- 实施策略包括跨专业参与、机构支持、融入临床工作流程和根据支付方结构选择模式。
核心结论
- 分子肿瘤委员会是肿瘤基因组医学临床实施的路径,也是肿瘤药师新兴的实践模式。
研究设计与样本
- 本文描述了威斯康星大学、印第安纳大学和Moffitt癌症中心由肿瘤药师开发并主导的三种精准医学实践模式。
主要发现
- 不同实践模式包括门诊、临床会诊服务和分子肿瘤委员会,以增强与卫生系统和支付结构的整合。
- 三种模式的共同点包括临床药师领导、具体治疗建议、超说明书用药获取和研究环节。
- 这些实践模式作为药学与医学学生及住院药师跨专业培训基地。
临床怎么用
- 关键实施策略包括跨专业参与、机构支持、融入临床工作流程和根据支付方结构选择模式。
- 肿瘤药学住院药师应接受基因组肿瘤学培训,药学院应扩大精准医学和基因组学教育,执业药师应获得精准医学继续教育机会。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Three different precision medicine practice models developed by oncology pharmacists are described, including strategies for implementation and recommendations for educating the next generation of oncology pharmacy practitioners. SUMMARY: Oncology is unique in that somatic mutations can both drive the development of a tumor and serve as a therapeutic target for treating the cancer. Precision medicine practice models are a forum through which interprofessional teams, including pharmacists, discuss tumor somatic mutations to guide patient-specific treatment. The University of Wisconsin, Indiana University, and Moffit Cancer Center have implemented precision medicine practice models developed and led by oncology pharmacists. Different practice models, including a clinic, a clinical consultation service, and a molecular tumor board (MTB), were adopted to enhance integration into health systems and payment structures. Although the practice models vary, commonalities of three models include leadership by the clinical pharmacist, specific therapeutic recommendations, procurement of medications for off-label use, and a research component. These three practice models function as interprofessional training sites for pharmacy and medical students and residents, providing an important training resource at these institutions. Key implementation strategies include interprofessional involvement, institutional support, integration into clinical workflow, and selection of model by payer mix. CONCLUSION: MTBs are a pathway for clinical implementation of genomic medicine in oncology and are an emerging practice model for oncology pharmacists. Because pharmacists must be prepared to participate fully in contemporary practice, oncology pharmacy residents must be trained in genomic oncology, schools of pharmacy should expand precision medicine and genomics education, and opportunities for continuing education in precision medicine should be made available to practicing pharmacists.
引用
- Walko C, Kiel PJ, Kolesar J, et al. Precision medicine in oncology: New practice models and roles for oncology pharmacists. Am J Health Syst Pharm. 2016. PMID: 27864201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。